As stated at the beginning of this chapter, studies on the role of HIF1α and HIF2α in leukemia failed to produce universal consent, especially in AML and CLL where contrasting evidence has been reported (Table 2). This evidence concerns the gene HIF1A and acute myeloid leukemia.